Mt 0169 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has removed a partial clinical hold that had been placed on a phase 1 trial investigating the safety and efficacy of MT-0169 as a potential therapeutic option in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

Eric pomaMolecular templates incMolecular templatesMt 0169Patients with relapsed or refractory multiple myelomaNon hodgkin lymphoma